Foundayo and Weight-Loss Maintenance: What Happens After You Reach Your Goal
There's no dedicated trial yet on what happens when someone loses weight on Foundayo itself and then stops taking it - the medicine is too new. What does exist is a related but narrower trial: evidence on what happens when people who'd already lost weight on an injectable GLP-1 medicine switch to Foundayo instead of staying on the injection. That's genuinely useful, but it isn't the same question as "do I have to take this forever," and this page is precise about exactly where the evidence reaches and where it doesn't.
Here's what the maintenance trial actually shows, what Foundayo's UK leaflet says about stopping, and what's honestly still unknown.
Key takeaways
- No trial has tested what happens if you lose weight on Foundayo itself and then stop it. The closest available evidence tested switching to Foundayo after an injectable GLP-1 medicine, not stopping Foundayo after starting on it.
- In that trial, people who switched to Foundayo kept most of the weight loss they'd already achieved, on average - considerably more than those given a placebo tablet instead.
- Foundayo's UK leaflet says not to stop without talking to your doctor first, and specifically that blood sugar can rise if you stop and have type 2 diabetes.
- No long-term, multi-year outcome data exists yet for Foundayo. It's a newly authorised medicine, and this page says so plainly rather than filling the gap with guesswork.
What the maintenance trial evidence shows
Foundayo's own maintenance evidence comes from a trial called ATTAIN-MAINTAIN, published in Nature Medicine in 2026. It didn't recruit people who'd lost weight on Foundayo and test what happened when they stopped. Instead, it recruited 376 adults who'd already spent 72 weeks losing weight on an injectable GLP-1 medicine - either tirzepatide (Mounjaro) or semaglutide (Wegovy) - in a separate trial, and had reached a plateau. Each person was then randomly assigned to switch to daily Foundayo, or to a placebo tablet, for a further 52 weeks, to see whether the weight loss they'd already achieved held.
| Prior injectable medicine | Weight loss kept on Foundayo | Weight loss kept on placebo |
|---|---|---|
| Tirzepatide (Mounjaro) | 74.7% | 49.2% |
| Semaglutide (Wegovy) | 79.3% | 37.6% |
In both groups, people who switched to Foundayo kept substantially more of their earlier weight loss than those switched to a placebo pill. That's a genuinely useful, orforglipron-specific finding, though what it shows is narrower than it might first appear.
The trial had no group that simply carried on with the original injectable, so it can't tell you whether switching to a tablet holds weight better, worse, or about the same as staying on an injection would have. And because everyone in this trial had already lost their weight on a different medicine first, it doesn't answer a related but different question: what happens if you lose weight on Foundayo itself, and then stop Foundayo itself. No trial has tested that yet.
At least one UK weight-loss website answers that exact question anyway, by quoting a withdrawal figure from a completely different medicine's own trial as if it applied directly to Foundayo. Results from one GLP-1 medicine's trial don't automatically transfer to another, even a related one, and this page doesn't borrow them. For the full initial weight-loss trial data behind Foundayo, including how the headline percentages are worked out, see Medino's in-depth look at the ATTAIN trial data.
What happens if you stop taking Foundayo, per the leaflet
Foundayo's UK patient information leaflet is direct about this. Under "If you stop taking Foundayo," it states: "Do not stop taking Foundayo without talking with your doctor. If you stop taking Foundayo, and you have type 2 diabetes, your blood sugar levels can increase."
That's two separate instructions, not one. The first applies to everyone, whatever the reason for considering it: don't just stop, talk to your doctor first. The second is specific to people with type 2 diabetes: stopping can let blood sugar rise again, a direct, practical consequence worth knowing about before any conversation about coming off treatment, not something to discover afterwards.
Neither instruction says why someone should or shouldn't stop, or how long is "enough." That's deliberately left to a conversation with a prescriber, based on your own health history and goals - not something this page, or any general guide, can responsibly settle for you.
Pharmacist insight: before that conversation, it helps to have three things ready: how the weight loss actually happened (diet and activity changes you plan to keep, versus changes that depended on the medicine's own appetite effect), whether you have type 2 diabetes or any other condition affected by blood sugar, and what support you'd want in place once that appetite effect wears off. That's usually more useful to a prescriber than simply saying you're thinking about stopping. -Alessandro Grenci, Superintendent Pharmacist at medino
If something feels wrong while tapering off or after stopping - not just "will I regain weight," but a genuine symptom - that's a different question, covered fully on Medino's guide to when to seek urgent help while taking Foundayo.
Why long-term outcome data doesn't exist yet, and what that means
Foundayo was authorised for use in the UK on 10 August 2026. Every trial behind it - ATTAIN-1, ATTAIN-2, ATTAIN-MAINTAIN - ran for months, not years: the longest, ATTAIN-1, followed people for 72 weeks. Nobody has multi-year outcome data for Foundayo, because Foundayo hasn't existed for multiple years yet. That's not a hidden flaw. It's simply true of every newly authorised medicine, and it deserves to be said outright rather than glossed over.
Practically, that means questions like "does the weight loss hold at five years," "what happens with repeated stop-start cycles," or "is there any cumulative effect from years of continuous use" don't have answers yet - not because anyone is withholding them, but because the studies that would answer them haven't had time to run. Real-world evidence will build as more people use Foundayo for longer. Until then, an honest gap is more useful than a confident-sounding guess.
| What the evidence currently shows | What it doesn't show yet |
|---|---|
| Switching to Foundayo after an injectable helps hold most of the weight already lost, over 52 weeks | What happens over multiple years, on any pathway |
| The UK leaflet's stopping instruction: talk to your doctor first, and a specific blood-sugar risk if you have type 2 diabetes and stop | What happens if you lose weight on Foundayo itself and then stop Foundayo itself |
| Foundayo's licensed indications and titration schedule | Long-term safety or effectiveness data beyond the trial periods |
Real-world perspective: what other people are saying
Everything above is clinical-trial evidence: controlled studies, reported as averages across groups of people. It's useful for understanding what's been tested and what the results were, but it isn't the same as hearing how maintenance actually feels day to day.
For that, Medino has a separate article gathering individual accounts from people using Foundayo and other GLP-1 medicines long-term: what people are saying about using Foundayo for weight maintenance. These are individual experiences, not a representative sample and not evidence of how the medicine works - they aren't a reason to continue, stop or switch treatment, and shouldn't be read as predicting what maintenance will be like for you. Treat it as a genuinely different kind of resource, illustrating what maintenance can feel like day to day, not a substitute for the evidence above, and not the other way round.
Frequently asked questions
Do I have to take Foundayo forever?
No fixed answer exists in the evidence. Foundayo doesn't come with a stated maximum or minimum length of treatment. Whether to continue, reduce, or stop is a decision made with your prescriber, based on how you're responding, your goals, and your health history. For the full picture on Foundayo generally, see Medino's complete Foundayo overview.
Will I definitely regain weight if I stop?
No trial has directly tested that exact scenario for Foundayo itself. The closest evidence, ATTAIN-MAINTAIN, found people who switched to Foundayo after an injectable kept most of their earlier weight loss over the following year, more than those given a placebo. It didn't test what happens after stopping Foundayo itself, so a precise answer for that specific situation isn't available yet.
Is there a lower "maintenance dose" once I reach my goal weight?
Foundayo's UK leaflet describes a titration schedule that increases towards a working dose, and a single instruction about stopping. It doesn't describe a separate, lower maintenance dose. Any change to your dose, including reducing it, should be discussed with your prescriber rather than assumed.
What should I actually do if I'm thinking about stopping?
Talk to your doctor or prescriber before you stop, not after. That's the leaflet's own instruction, and it applies whatever your reason for considering it. It matters even more if you have type 2 diabetes, since stopping can let blood sugar rise again.
